Literature DB >> 9404850

Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin.

D J Santa Cruz1, P D Hamilton, D J Klos, J A Fernandez-Pol.   

Abstract

We have previously shown that human metallopanstimulin (MPS-1) is a ubiquitous 9.4-kDa multifunctional ribosomal S27/nuclear "zinc finger" protein which is expressed at high levels in a wide variety of cultured proliferating cells and tumor tissues, including melanoma. In the present study, we have examined the expression of the MPS-1 protein in various types of human benign and malignant melanocytic lesions of the skin. The expression of the MPS-1 protein was studied by immunohistochemistry using specific anti-MPS-1 antibodies. We found that in benign nevi, the staining is weak and in a gradient; most often, only type A melanocytes stain positive. The B and particularly the C types are negative. Remarkably, congenital nevi show a similar gradient staining of regular benign nevi, but in addition one example showed intensely positive dermal nodules adjacent to areas of negative melanocytes. In melanomas, the staining patterns for MPS-1 are more complex. While some melanomas stain evenly and intensely positive, others have remarkably variable expression of MPS-1. The scattered melanocytes migrating to the upper layers of the epidermis are usually intensely positive. In summary, benign lesions stain in an orderly pattern with staining gradients that correlate with the cellular differentiation of the nevi. Malignant melanomas have an erratic, often intense staining that also correlates with the disorderly growth of these neoplasms. These differential results indicate that the MPS-1 antigen is a useful marker for melanocytic lesions at the immunohistochemical level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404850     DOI: 10.1111/j.1600-0560.1997.tb01457.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  9 in total

1.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

Review 2.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  A highly recurrent RPS27 5'UTR mutation in melanoma.

Authors:  Ken Dutton-Regester; Jared J Gartner; Rafi Emmanuel; Nouar Qutob; Michael A Davies; Jeffrey E Gershenwald; William Robinson; Steven Robinson; Steven A Rosenberg; Richard A Scolyer; Graham J Mann; John F Thompson; Nicholas K Hayward; Yardena Samuels
Journal:  Oncotarget       Date:  2014-05-30

4.  Functional analysis of RPS27 mutations and expression in melanoma.

Authors:  Alfredo Floristán; Leah Morales; Douglas Hanniford; Carlos Martinez; Elena Castellano-Sanz; Igor Dolgalev; Alejandro Ulloa-Morales; Eleazar Vega-Saenz de Miera; Una Moran; Farbod Darvishian; Iman Osman; Tomas Kirchhoff; Eva Hernando
Journal:  Pigment Cell Melanoma Res       Date:  2019-11-22       Impact factor: 4.693

5.  Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation.

Authors:  Yaël Mamane; Emmanuel Petroulakis; Yvan Martineau; Taka-Aki Sato; Ola Larsson; Vinagolu K Rajasekhar; Nahum Sonenberg
Journal:  PLoS One       Date:  2007-02-21       Impact factor: 3.240

6.  Metallopanstimulin as a marker for head and neck cancer.

Authors:  Brendan C Stack; Christopher S Hollenbeak; Christopher M Lee; Frank R Dunphy; Val J Lowe; Paul D Hamilton
Journal:  World J Surg Oncol       Date:  2004-12-14       Impact factor: 2.754

7.  Phosphoproteomic analysis of the antitumor effects of ginsenoside Rg3 in human breast cancer cells.

Authors:  Mingjin Zou; Jing Wang; Jidong Gao; Hui Han; Yi Fang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

8.  Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?

Authors:  Jonas Feldheim; Almuth F Kessler; Dominik Schmitt; Ellaine Salvador; Camelia M Monoranu; Julia J Feldheim; Ralf-Ingo Ernestus; Mario Löhr; Carsten Hagemann
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

Review 9.  Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

Authors:  Shivshankari Rajkumar; Ian R Watson
Journal:  Br J Cancer       Date:  2016-06-23       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.